Related Experiment Video
Updated: Aug 11, 2026

A Murine Model of Irreversible and Reversible Unilateral Ureteric Obstruction
Published on: December 20, 2014
Increased osteopontin expression following renal ablation is attenuated by angiotensin type 1 receptor antagonism
Zemin Cao1, Alison Cox, Fabrice Bonnet
1Department of Medicine, University of Melbourne, Austin & Repatriation Medical Center, Heidelberg West, Vic., Australia. cao@austin.unimelb.edu.au
Abstract:
Osteopontin is an extracellular matrix protein that is upregulated in renal injury. The aim of this study was to explore the renal expression of osteopontin in a model of progressive renal injury following subtotal nephrectomy (STNx) in rats and the effects of angiotensin type1 (AT1) receptor antagonist irbesartan on osteopontin expression. STNx or a sham operation was performed in 8-week-old Sprague-Dawley rats. STNx rats were given either irbesartan (15 mg/g) or no treatment for 12 weeks. Upregulation of osteopontin mRNA expression was observed in injured renal tubules as assessed by in situ hybridization (42 +/- 8 dpm/mm(2) v.s. control 7.7 +/- 0.6 dpm/mm(2), p < 0.01). Increased osteopontin expression was closely related to infiltration of monocytes/macrophages and increased cellular proliferation. Double immunohistochemical staining demonstrated co-existence of proliferating cell nuclear antigen and osteopontin positive staining in individual cells in kidney sections from STNx rats. The increase in osteopontin expression was inhibited by the AT1 receptor antagonist irbesartan (6.9 +/- 1.2 dpm/mm(2)), associated with attenuation of impaired renal function and pathology as well as decreased monocyte/macrophage infiltration and cellular proliferation. These findings suggest that osteopontin is upregulated in STNx rats and is reduced by AT1 receptor antagonism.
Insights
Osteopontin, a protein linked to kidney injury, is upregulated in rats with progressive renal damage. Treatment with irbesartan, an angiotensin type 1 receptor antagonist, reduced osteopontin levels and improved kidney function.
Area of Science:
- Nephrology
- Molecular Biology
- Pathology
Background:
- Osteopontin is an extracellular matrix protein implicated in renal injury.
- Its role in progressive renal damage requires further investigation.
Purpose of the Study:
- To investigate renal osteopontin expression in a rat model of progressive renal injury after subtotal nephrectomy (STNx).
- To evaluate the effect of the angiotensin type 1 (AT1) receptor antagonist irbesartan on osteopontin expression and renal pathology.
Main Methods:
- Subtotal nephrectomy (STNx) or sham operation in Sprague-Dawley rats.
- Administration of irbesartan (15 mg/g) or no treatment to STNx rats for 12 weeks.
- In situ hybridization and double immunohistochemical staining to assess osteopontin mRNA, monocyte/macrophage infiltration, and cellular proliferation.
Main Results:
- STNx induced significant upregulation of osteopontin mRNA in injured renal tubules.
- Increased osteopontin expression correlated with monocyte/macrophage infiltration and cellular proliferation.
- Irbesartan treatment inhibited osteopontin upregulation, attenuated renal dysfunction and pathology, and reduced inflammation and proliferation.
Conclusions:
- Osteopontin is upregulated in progressive renal injury following STNx in rats.
- AT1 receptor antagonism with irbesartan effectively reduces osteopontin expression and ameliorates renal damage.
Related Concept Videos
Osteoclasts in Bone Remodeling
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury II: Pathophysiology

